Operated by Bellevue Asset Management AG, BB Biotech AG functions as an equity fund primarily concentrating its global investments on publicly listed firms pioneering modern biotechnology, specifically in the fields of medications and diagnostics. Its portfolio is meticulously constructed using a thorough fundamental analysis approach. This Swiss-domiciled fund was established on November 9, 1993.